Selected transactions
Therapeutic Area
Collaboration between A2P Sciences and Professor Patrizia d’Alessio to develop an innovative anti-RAGEs formula, leveraging their respective expertise in protein glycation inhibition and cellular senescence, with jointly owned research outcomes and IP development.
Exclusive financial advisor to Suisselle SA in connection with the sale of a 10% equity interest to Sihuan Pharmaceutical Holdings Group Ltd., a leading integrated pharmaceutical group in China.
Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.
Exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe.
Exclusive Financial Advisor to ERC for a share capital increase subscribed by UHNWI investors.
Exclusive Financial Advisor in the acquisition of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company.
Exclusive Financial Advisor to NicOx SA on the acquisition of Laboratoires Doliage and concurrent entry into ancillary agreements with the Seller.
Exclusive Financial Advisor in the acquisition of Marinomed GmbH, a Biotechnology company developping anti-viral and immunological treatments, including Carragelose® anti-viral eye drop program.
Exclusive Financial Advisor to Alternext listed Novacyt SA on a merger with Lab21 Ltd.
Exclusive Financial Advisor to NicOx SA on the acquisition of Eupharmed S.r.l for an upfront consideration combined with a performance earn-out.
Exclusive Financial Advisor to Ekomir’s shareholders on the sale of the company to Valeant Pharmaceuticals.
Financial Advisor to Vemedia’s shareholders on the sale of a 78% stake to IK Investment Partners and a minority MBO to CEO.